South Texas Veterans Health Care System Joins Test Validation Trial of bioAffinity’s CyPath® Lung

PUBLISHED ON October 23, 2018

SAN ANTONIO, TX (October 23, 2018) bioAffinity Technologies, a privately held biotech company, today announced that the South Texas Veterans Health Care System (STVHCS), which is affiliated with the federal Department of Veterans Affairs (VA) health care system, will be a clinical collection site for the Company’s test validation trial of CyPath® Lung, a non-invasive test for the early detection of lung cancer.

read more

BioAffinity Licenses Lung Cancer Test to Precision Pathology Services

PUBLISHED ON October 12, 2018

360Dx (October 10, 2018) BioAffinity Technologies today said that it has inked a licensing agreement with Precision Pathology Services for the continued development and commercial sale of its CyPath Lung assay as a laboratory-developed test used for the diagnosis of early-stage lung cancer.

read more

Rising SA biotech on threshold of national product launch

PUBLISHED ON October 12, 2018

San Antonio Business Journal (October 10, 2018) BioAffinity Technologies, a San Antonio-based biotech, has struck a deal with another local company, Precision Pathology Services, to sell its CyPath Lung device nationally. The arrangement furthers bioAffinity's progress toward making its market debut with the new early-cancer detection product.  

read more

Mount Sinai Joins Test Validation Trial of bioAffinity’s CyPath® Lung

PUBLISHED ON September 22, 2018

SAN ANTONIO, TX (September 18, 2018) bioAffinity Technologies, a privately held biotech company, today announced that the Icahn School of Medicine at Mount Sinai (ISMMS) in New York, NY, will be a clinical collection site for the Company’s test validation trial of CyPath® Lung, a non-invasive test for the early detection of lung cancer. The study will be performed under the direction of the Clinical Trials Office in the Department of Medicine.

read more

bioAffinity Technologies is proud to play a part in the University of Texas Health video highlighting our impressive research collaboration to uncover the mechanisms of cancer. The collaboration with the University of Texas, a leader in innovation, has led to exciting advancements that further the development and commercialization of our life-saving tests and treatments for cancer. In this video, you’ll see physicians, scientists, and bioAffinity Technologies CEO Maria Zannes discuss how medical breakthroughs are being commercialized and made available to those who need them, including more about how we’re moving forward with our CyPath® diagnostic tests and OncoSelect® therapeutics.